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Background: Magnetic resonance imaging (MRI) is the gold standard for 
assessment of perianal fistulising Crohn’s disease (CD). The Van Assche index is 
the most commonly used MRI fistula index. 
 
Aims: Assess the reliability of the Van Assche index, modify the instrument to 
improve reliability and create a novel index for fistulizing CD. 
 
Methods: A consensus process developed scoring conventions for exisiting Van 
Assche index component items and new items. Four experienced radiologists 
evaluated 50 MRI images in random order on three ocasions. Reliability was 
assessed by estimates of intraclass correlation coefficients (ICCs). Common sources 
of disagreement were identified and recommendations made to minimise 
disagreement. A mixed effects model used a 100 mm visual anologue scale (VAS) 
for global severity as outcome and component items as predictors to create a 
modified Van Assche index. 
 
Results: Intraclass correlation coefficients (95% confidence intervals) for intra-rater 
reliability of the original and modified Van Assche indices and the VAS were 0.86 
(0.81–0.90), 0.90 (0.86–0.93) and 0.86 (0.82–0.89). Corresponding ICCs for inter-
rater reliability were 0.66 (0.52–0.76), 0.67 (0.55–0.75) and 0.58 (0.47–0.66). 
Sources of disagreement included number, location, and extension of fistula tracts, 
and rectal wall involvement. A modified Van Assche index (range 0–24) was created 
that included seven component items. 
 
Conclusions: Whereas “almost perfect” intra-rater reliability was observed for the 
assessment of MRI images for fistulising CD using the Van Assche index, inter-rater 
reliability was considerably lower. Our modification of this index should result in a 
more optimal instrument. 
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INTRODUCTION 
 
Approximately one-third of patients with Crohn’s disease (CD) will develop a perianal 
fistula in their lifetime.1,2  This relatively common disease complication is associated 
with significant morbidity and substantially impaired quality of life. Medical therapy is 
only partially effective, such that patients frequently undergo surgery to control 
symptoms and disease-related complications. Therefore, more effective treatment 
approaches are needed that will require evaluation in well-designed randomised 
controlled trials.   
In this respect, the lack of a robust and validated outcome measure has 
constrained research in this area. In clinical practice, pelvic magnetic resonance 
imaging (MRI)  has an established role for the evaluation of patients with perianal 
fistulas and is used to make clinical decisions and assess changes in disease 
state.3,4 While several scoring systems, such as the Fistula Drainage Assessment 
and the partially validated Perianal Disease Activity Index, have been used to 
quantify clinical parameters, far fewer have been developed for MRI and they also 
lack standardised definitions of descriptor items.5 The most frequently used MRI 
index is the Van Assche index, originally developed to fulfill the need for an 
instrument that could measure response of perianal fistulising CD to medical 
therapy.6 The components of the index, based primarily upon radiological expertise 
and the classification of perianal fistulas by Parks et al, were shown to be reliable in 
the initial small (n=18) study.7,6 In a subsequent small study, in addition to the 
original Van Assche index components Horsthuis et al included assessment of T1-
weighted post-gadolinium hyperintensity and the presence of an infiltrate as potential 
measures of inflammatory activity. Although this study confirmed the Van Assche 
index was suitable for use as measure of response to therapy in clinical practice, the 
4 
 
validity of the individual index components was not assessed due to sample size 
limitations, and no conclusions could be made on the value of the additional 
inflammatory components.8 Ng et al also found the total Van Assche index partially 
responsive to change with treatment with anti-tumor necrosis factor therapy, 
although they did not examine the operating properties of the individual index items 
and it was evident that the overall index was insensitive to change in some patients, 
including those with a 50%-80% reduction in track volume.9  
 In 2013, the World Congress of Gastroenterology working group formulated a 
multi-disciplinary consensus statement for classifying, diagnosing, and treating 
fistulising CD and identified the need for a  validated index for measuring response 
to therapy as a high priority.10 In the first steps towards this goal we: (1) developed 
standardized scoring conventions for existing components of the Van Assche index 
and assessed their reliability in a convenience sample of MRI examinations in 
patients with fistulising perianal CD; (2) identified items with highest disagreement in 
the Van Assche index, developed modifications to these and included new items 
through a formal consensus process, and then (3) created a modified Van Assche 
index. 
MATERIALS AND METHODS 
Study population 
Fifty MRI scans carried out in 50 patients with active perianal fistulising CD between 
July 2011 and November 2013 at the Academic Medical Center, Amsterdam, The 
Netherlands were evaluated. The sample included a wide range of disease 
complexity and anatomical classification (see Supplementary Table 1). The 
indications for which the scans were performed included active perianal symptoms 
and evaluation of response to previous medical or surgical interventions. Scans with 
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missing sequences, and those from patients who did not receive intravenous 
contrast due to allergy or who had undergone ileoanal pouch formation for colonic 
CD were excluded (Supplementary Figure 1). Of the 50 scans, 45 were collected in 
a consecutive manner with a further 5 scans hand-selected to ensure that all of the 
fistula classifications were represented in our cohort. These additional scans were 
selected based on the description of the reporting radiologist for the purposes of 
clinical practice, and were not selected by the expert central readers and had not 
been previously reviewed by the readers for other purposes. These scans included 
intersphincteric, extrasphincteric, suprasphicteric, and two transsphincteric fistulas. 
One of these was considered complex. Ideally, more of the less commonly occurring 
fistula subtypes would have been included in our final set of scans but they, by their 
very nature, occur infrequently and were therefore difficult to identify.  
MRI acquisition technique 
MRI scans were performed on a 1.5-T scanner (Magnetom Avanto, Siemens, 
Erlangen, Germany) according to a standardized protocol for perianal fistulising 
disease, consisting of the following sequences: T2-weighted turbo spin echo (TSE) 
sequences in the sagittal, coronal and transverse plane, a fat-saturated T2-weighted 
TSE spectral adiabatic inversion recovery sequence and a post-contrast fat-
saturated T1-weighted TSE sequence in the transverse plane (Supplementary Table 
2). A combination of saturated and unsaturated T2 sequencing was used to 
discriminate between fibrosis, edema and fat. 
The post contrast sequences were performed 60 seconds after intravenous 
administration of 0.1 mL/kg gadobutrol (Gadovist 0.1 mmol/mL, Bayer Schering 
Pharma, Berlin, Germany). The coronal and axial sequences were parallel and 
orthogonal to the anal sphincter axis, respectively. A spasmolytic agent (Buscopan, 
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Boehringer Ingelheim, Ingelheim, Germany) was used to reduce bowel peristalsis 
and motion artifacts. All MRI examinations were anonymized and uploaded to a 
secure central viewing system. 
Scoring conventions and modification to the original Van Assche index  
Based upon face validity and expert opinion of radiologists in this field (CS, CYN, JR, 
JS, SAT), we developed standardized scoring conventions for component items of 
the original Van Assche index, and included additional descriptors to these items as 
modifications. We also incorporated novel items considered potentially important 
based on face validity that might also be responsive to change after a therapeutic 
intervention through the same expert opinion process. A pilot study followed whereby 
four expert abdominal radiologists (CS, CYN, JR, SAT) with experience in fistula MRI 
evaluated four scans (that were not subsequently included in the 50 study scans), 
before refining the items/descriptors during subsequent discussion, which took place 
prior to initiation of the reliability study. These discussions were conducted in a 
manner consistent with a Delphi process although no formal voting was carried out. 
The adapted version of the Van Assche index is henceforth referred to as the 
modified Van Assche index. 
Reliability study 
Four expert abdominal radiologists (CS, CYN, JR, SAT) with experience in fistula 
MRI and blinded to clinical information independently reviewed 50 MRI examinations 
in triplicate in random order and assessed disease activity using both the original 
and the modified Van Assche index (Table 1). 
The study radiologists also completed three visual analogue scale (VAS) 
assessments for each scan as part of their evaluations. The first was aimed at 
evaluating the overall severity of the inflammatory component of the perianal disease 
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(0 mm = no active inflammatory disease, 100 mm = severe active inflammatory 
disease). The second assessed the overall complexity (0 mm = minimal complexity, 
100 mm = highly complex). The final VAS assessment was a combined global 
assessment that took account of both inflammatory activity and complexity (0 mm = 
no perianal disease, 100mm = worst perianal disease encountered), and was the 
score used as the gold standard comparator. In addition, the presence or absence of 
imaging artifacts was recorded, as was image quality, using a three-point scale 
(good, adequate, inadequate).  
Intra-and inter-rater reliability statistics were calculated and compared for the 
total index and the component items of the original and modified versions of the Van 
Assche index and the three features assessed with the VAS. Index components with 
”fair” or ”poor” inter-rater reliability based on the criteria of Landis and Koch, whereby 
intraclass correlation coefficients (ICCs) of <0.0, 0.0–0.20, 0.21–0.4, 0.41–0.6, 0.61-
0.8, and >0.81 constitute ‘poor,’ ‘slight,’ ‘fair,’ ‘moderate,’ ‘substantial’ and ‘almost 
perfect’ reliability, respectively, were subsequently discussed during a second 
consensus meeting of the study radiologists. Consensus statements were generated 
during this meeting, and RAND appropriateness methodology was used to refine 
items accordingly.11 RAND appropriateness methodology uses a modified Delphi 
panel approach to combine the best available evidence and personal clinical 
experience of experts. The panel facilitates decision making through an iterative 
process in which questions are raised and viewpoints discussed. Experts then vote 
on the appropriateness of statements developed during this process with an aim to 
reach consensus according to predefined criteria. As part of the process, rules were 
developed that would improve consistency of reading of MRI images of perianal 
fistulas. Other potential sources of disagreement among the radiologists were 
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explored by identifying “outlier” images that led to the poorest inter-rater reliability. 
These outlier images were reviewed by one expert reader (JS) for potential common 
sources of variance. 
Statistical methods 
Clinical characteristics were assessed using descriptive statistics. Intra- and inter-
rater reliability were quantified using intraclass correlation coefficients (ICCs), which 
are equivalent to weighted Kappa statistics in the case of ordinal data.12 For each 
component item, point estimates of intra- and inter-rater ICCs were concurrently 
estimated using a two-way random effects model with interaction.13 Associated two-
sided 95% CIs were obtained using the non-parametric percentile bootstrap method 
with 2000 samples obtained with replacement at the level of the image to maintain 
data structure.  This approach is commonly known as the cluster bootstrap 
method.14 The degree of reliability was interpreted based on Landis and Koch 
benchmarks. These empirical benchmarks were originally developed for grading 
kappa statistics and have now become widely adopted for assessment of ICCs.  
 The modified Van Assche index was created using the VAS for global 
assessment of severity as the outcome criterion. To account for the data structure 
that each MRI scan was read three times by each of the four readers, a mixed 
effects model was adopted with fixed effects including the nine modified Van Assche 
items and random effects including MRI scan, reader and their interaction. The 
model fit was assessed using residual diagnostics. The Bayesian Information 
Criterion (BIC) using maximum likelihood estimation was used to assess the quality 
of fit of the model. Regression coefficients were standardized by dividing by the 
smallest coefficient to facilitate easy calculation of the modified Van Assche index. 
Sample size was estimated using the method proposed by Zou.15 Assuming a true 
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ICC of 0.75, rating of 50 MRI sequences from 50 patients by 4 radiologists would 
yield an 92% chance of obtaining a two-sided 95% lower confidence bound for the 
ICC of 0.55, a value considered to be ‘moderate’ according to the Landis and Koch 
benchmarks.  
Ethical considerations 
The use of the scans for the purposes of this study was approved by the medical 
ethics committee at the Academic Medical Centre and additional patient consent for 
use of images was not required. 
RESULTS 
Modified Van Assche index 
Scoring conventions, modifications, and addition of novel items to the original Van 
Assche index based upon the expert consensus to create the modified Van Assche 
index are shown in Table 1. Core items from the Van Assche index were all retained, 
although the “Collections” item was modified and incorporated into a new item 
“Inflammatory mass” as described in Table 1 and below. Modifications to the original 
Van Assche index included: (1) the addition of “submucosal” to the location 
component, as well as creation of separate categories for extra- and intersphincteric 
locations; (2) addition of “horseshoe configuration” to the extension component; (3) 
inclusion of extensions in addition to the primary tract in the assessment of the 
hyperintensity of T2-weighted images; (4) addition of “increased signal intensity” to 
the rectal wall involvement component. New items added to the Van Assche index 
were: (1) presence of a recto/anovaginal tract; (2) presence of an inflammatory mass 
in conjunction with assessment of size of collections; (3) hyperintensity of the 
primary tract or extensions on post-contrast fat saturated T1-weighted images; (4) 
assessment of the dominant feature of the primary tract and extensions.  
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Participant characteristics 
Participant demographics are outlined in Supplementary Table 3. The mean age of 
the patients was 39 (range, 19-75 years), 48% (24/50) were male, the mean CD 
disease duration was 14 years (range, 0.5-47 years) and the mean duration from first 
fistula diagnosis was 9 years (range, 1 month-39 years). Most participants had prior 
perianal surgery (66%), and more than half (56%) were under treatment with an anti-
tumour necrosis factor (TNF) agent. The mean overall assessment of disease 
severity based on the VAS was 4.36 (range 0.20 to 9.80).  
MRI image quality 
A total of 600 reads were performed by the four expert radiologists. Of these, 565 
(94.2%) were considered to be of good quality, 30 (5.0%) were adequate and 5 
(0.8%) were considered inadequate. Only 2.2% of reads reported a missing 
sequence or plane and imaging artefact was present in 5%. Four cases contained 
ano-vaginal fistulas. 
Reliability results for overall indices 
Intraclass correlation coefficients and 95% confidence intervals for intra- and inter-
rater reliability for scoring of the VAS and the total original and modified Van Assche 
indices and their components are shown in Table 2.  
While almost perfect intra-rater reliability was observed for all of the VAS-
based assessments, inter-rater reliability ranged from moderate to substantial. The 
lowest inter-rater ICC was observed for assessment of complexity of disease (0.41, 
95% CI 0.28-0.51), followed by global assessment (0.58, 95% CI 0.47-0.66) and 
severity of inflammatory perianal disease activity (0.64, 95% CI 0.53-0.72). Intra- and 
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inter-rater reliability for the original Van Assche index were almost perfect (ICC 0.86, 
95% CI 0.81-0.90) and substantial (0.66, 95% CI 0.52-0.76). Intra- and inter-rater 
reliability for the modified Van Assche index) were both numerically higher than for 
the original Van Assche index, although the degree of intra- and inter-rater reliability 
according to the Landis and Koch criteria was unchanged and remained almost 
perfect (0.90, 95% CI 0.86-0.93) and substantial (0.67, 95% CI, 0.55-0.75), 
respectively. 
Reliability of index component items 
Intra-rater reliability was substantial to almost perfect for all component items of the 
original Van Assche index except for fistula location which was moderate (0.59, 95% 
CI 0.48-0.70) prior to application of standardized scoring conventions adapted from 
the St Mark’s classification, and which improved to substantial after application of the 
conventions (0.70, 95% CI 0.59-0.79) (Table 2).  
Inter-rater reliability was slight to moderate for all component items of the 
original Van Assche index, with the exception of collections, which was substantial 
(0.61, 95% CI 0.46-0.73). Inter-rater reliability for the assessment of fistula location 
improved from fair to moderate (0.30, 95% CI 0.18-0.41 vs. 0.46, 95% CI 0.29-0.59 
respectively) and fistula extension improved from slight to moderate (0.17, 95% CI 
0.06-0.28 vs. 0.48, 95% CI 0.33-0.61 respectively) (Table 2 and Supplementary 
Table 4) with the modified version of the Van Assche index. Inter-rater reliability for 
the assessment of hyperintensity of tracts on fat-saturated T2-weighted images 
remained unchanged, and decreased for the assessment of rectal wall involvement 
with the modified van Assche index despite modification and inclusion of 
standardized scoring conventions.  
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 Four new items were incorporated into the modified van Assche index based 
upon the expert consensus, specifically: (1) presence of a recto/anovaginal tract; (2) 
inflammatory mass (which incorporated the item of collections from the original van 
Assche index plus additional features); (3) hyperintensity of the primary tract or 
extensions on post-contrast fat saturation T1-weighted images; and (4) dominant 
feature of the primary tract and extensions. Assessment of these new items was 
associated with slight-to-moderate inter-rater reliability (Table 2 and Supplementary 
Table 4), with the lowest ICCs observed for the presence of an ano/rectovaginal 
tract (0.15, 95% CI 0.02-0.25). Higher inter-rater ICCs were observed for 
assessment of hyperintensity of the primary tract or extensions seen on post-
contrast fat saturated T1-weighted images (0.40, 95% CI 0.27-0.50) and assessment 
of the dominant feature of the primary tract and extensions (0.37, 95% CI 0.23-0.49). 
The highest inter-rater ICC was observed for inflammatory mass (0.59, 95% CI 0.43-
0.71). 
Sources of disagreement and consensus process  
 
The consensus process, which involved participation of four experts (CAJP, ST, JR, 
JS), a gastroenterologist (GDH) and a moderator (VJ) was conducted using RAND 
appropriateness methodology to review items contributing to the greatest variance in  
an attempt to understand and minimise the sources and improve inter-rater reliability. 
In addition, nine MRI scans responsible for the greatest disagreement based on their 
effect on the overall estimation of ICCs were reviewed by a single expert reader (JS) 
to identify features that may have contributed to disagreement. As a result of this 
process, modifications were made to four specific items. Subsequently, readers voted 
on the appropriateness of the modified items (Supplementary Table 5). The 
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recommendations of the experts and the proposed modified items are described in 
Table 3 and Supplementary Table 6.  
 
 
 
 
Final modified van Assche index based on mixed effects modeling 
 
The mixed effect model building process began with all 9 items described in Table 1. 
Coefficient estimates and associated inferential statistics for these items are shown in 
Table 4. Negligible and statistically insignificant coefficients were observed for 
number of fistula tracts and location, and presence of a recto/anovaginal tract and 
hyperintensity on post contrast T1-weighted images were only marginally significant 
(p = 0.053 and 0.051, respectively). The model was then refitted with the remaining 
five component items, resulting in numerically large and statistically significant 
coefficients (Table 4). The final modified Van Assche index based on mixed effects 
modeling included “extension,” “hyperintensity on T2-weighted images,” “rectal wall 
invovlement,”  “inflammatory mass,” and “dominant feature of primary tract and 
extension”. Intra-class correlation coefficients for intra- and inter-rater reliability of the 
modified Van Assche index based on the model were 0.89 (0.85 to 0.92) and 0.67 
(95% CI 0.56 to 0.75), consistent with nearly perfect and “substantial” reliability, 
respectively. An overall score for this index is calculated as the sum of the products of 
the observed item scores and the corresponding standardized scores. Total scores 
range from 0 to 20. 
 
DISCUSSION 
 
Development of novel therapies for patients with perianal fistulising disease is a 
large unmet need in the management of CD. There are currently no therapies 
approved by the US Food and Drug Administration, although promising new 
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approaches to treatment are entering phase 3 programs.16 In clinical practice, MRI 
has an essential role in the assessment of perianal disease and thus development of 
a fully validated MRI-based evaluative instrument with well-defined operating 
properties is essential for both for the evaluation of clinical disease activity and for 
the efficient study of new treatments in clinical trials. Besides the Van Assche index, 
to our knowledge the only other previously described MRI index for assessment of 
the severity of perianal disease is the index described by Ng and colleagues.9 In 
their study, as well as highlighting that the van Assche index was insensitive to 
change in some patients in whom there was radiological evidence of fistula 
improvement, Ng et al also semi-quantitatively described within-patient fistula 
changes in response to therapy as “healed (absence of high-signal tracks on fat 
saturated T2 sequences)” or “improved,” “unchanged,” or “worse” in cases where 
fistula tracks remained visible. Both indices have been used to define endpoints in 
clinical trials despite the lack of a complete characterization of their operating 
properties or standardized methods for scoring. These limitations informed the need 
for our study. A critical step in index development is to determine the reliability of 
index component items, which is defined as the extent to which raters are able to 
consistently distinguish between study subjects and the degree to which repeated 
measurements provide similar results.17 
 We found “almost perfect” intra-rater reliability for the original Van Assche 
index, and “substantial” reliability for all of the individual component items with the 
exception of fistula location. In contrast, the corresponding inter-rater reliability was 
lower, and ranged from slight to substantial, with the lowest reliability observed for 
assessment of fistula extension (0.17, 95% CI 0.06-0.28) and the best reliability 
observed for assessment of collections (0.61, 95% CI 0.46-0.73). This discordance 
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between intra- and inter-rater reliability is not unexpected as raters are more likely to 
agree with themselves than one another, however it provides an opportunity to 
improve inter-rater item scoring through a systematic consensus process when 
substantial intra-rater reliability exists. This is an important consideration if multiple 
readers are required out of logistical considerations in the conduct of a clinical trial or 
in clinical practice when different radiologists read different scans originating from 
the same patient. Accordingly, we identified individual items in the original Van 
Assche index with suboptimal inter-rater performance and attempted to improve 
them by developing and including standardized scoring conventions and 
modifications through a systematic consensus process. Specifically, the inter-rater 
reliability of “location” and “extension,” were substantially improved (see Tables 1 
and 2). For assessment of fistula extension, the experts felt that definition of the ano-
rectal junction was a potential source of disagreement among readers. Two cases 
with considerable variability for the identification of supra- versus infralevatoric 
extensions are shown in Figures 1 and 2. To provide superior differentiation 
between these extensions, we defined the ano-rectal junction as the connection of 
the levator plane to the ano-rectum. This anatomical location is delineated by a two 
arrows in Figure 3.  
Despite the application of scoring conventions and inclusion of an additional 
item (increased signal intensity), ICCs for inter-rater reliability for the assessment of 
rectal wall involvement decreased marginally in the modified Van Assche index. Poor 
rectal distension and subjectivity in discerning signal intensity relative to surrounding 
planes were potential sources of disagreement considered by the experts. Although 
this item remained significant in the mixed effects modelling approach, it was re-
named as “absence or presence of proctitis” and re-defined based on the expert 
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RAND consensus to improve reliability (Supplementary Table 6). The proctitis item is 
a composite score of several features that had fair inter-rater reliability in this study. 
However, improved inter-rater reliability (with the exception of fair-to-moderate inter-
rater reliability for perimural enhancement) was observed in a separate recently 
published study on individual MRI features in Crohn’s proctitis that were significantly 
correlated with endoscopy. As the inter-rater reliability of this item was not tested in 
this study, it may be worthwhile to further explore a more detailed evaluation of 
proctitis.18  No standardized definitions or modifications were initially applied to the 
item “number of fistula tracts,” since this assessment was considered to be self-
explanatory. It was thus somewhat unexpected that only “fair” inter-rater reliability 
was observed for this item. We subsequently modified this item to include the 
descriptors “single, unbranched” or “complex” based on expert opinion regarding the 
difficulty associated with differentiating a single tract with multiple braches, from 
disease with multiple tracts, although this item was not statistically significant in the 
mixed effects model building, and was not included as an item in the final index. 
Inter-rater reliability for the novel items included in the modified Van Assche 
index ranged from slight to moderate. Modifications to further improve reliability are 
shown in Supplementary Table 6. Although there was no expert consensus on the 
appropriateness of the inclusion of the absence or presence of an ano/rectovaginal 
this item was not statistically significant in the mixed effects model building and was 
excluded from the final index. The relatively poorer inter-rater reliability for this item 
was thought to be likely due to the difficulty associated with identifying these tracts, 
which are typically short in length, small in diameter and obscured between vessels. 
Free drainage to the vagina and rectum, and lack of fluid within the tract were also 
thought to contribute to difficulty in identification of these tracts. 
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Limitations of our study should be acknowledged. Firstly, images for the study 
were acquired from a tertiary center, which is a regional center for complex cases. 
Accordingly, some of the MRI’s reviewed were considered to represent severe 
disease, where complexity is likely to be higher than the general IBD population. 
However, the MRI scanners, sequences and protocols used in this study are 
consistent with those used in most centers. This did not include diffusion weighted 
imaging and its potential added value to the protocol performed in this study has not 
yet been clearly demonstrated. Secondly, the scans were carried out for a range of 
indications and included patients who were receiving various treatments, including 
anti-TNF agents. It is possible that these factors could have introduced bias (for 
example, attenuation of inflammatory activity due to treatment effect). Conversely, 
this heterogeneity may also serve to increase the generalizability of our results as 
many MRI assessments are performed in patients receiving anti-TNF therapy. 
Thirdly, whilst the quality of the majority of MRI images was judged to be acceptable, 
the method by which we evaluated quality (good, adequate or inadequate) was 
subjective and did not include standardized definitions. Fourthly, readers were highly 
experienced IBD radiologists and thus the results may not be generalizable to other 
readers; however since the objective of this exercise was to refine operating 
characteristics of an existing MRI fistula scoring system for use in clinical trials, this 
situation mandated the need for specialist radiologists. Fifthly, we acknowledge that 
the number of scans included was modest (n=50), however, the total number of 
reads was substantial (n=600), owing to the reading of scans in triplicate by all four 
radiologists which was, by design, based upon formal statistical methods for a 
reliability study. Finally, we were unable to test the responsiveness of the new index, 
which would require comparing baseline and post-treatment MRI’s in patients 
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receiving a treatment of known efficacy, ideally in a randomised, placebo-controlled 
trial. Once such a dataset becomes available, the responsiveness of the modified 
van Assche index can be tested and a minimally important score change identified. 
Furthermore, it has not escaped our attention that MRI-defined disease activity may 
be an important prognostic indicator since it provides relevant information about 
deep-tissue inflammation and healing and may provide important information about 
progressive structural damage. Nevertheless, several questions remain about the 
optimal timing for MRI assessment, with preliminary data indicating that this may be 
considerably longer than traditional clinical or endoscopic follow-up periods.9 
In conclusion, we found “substantial” to “almost perfect” intra-rater reliability 
amongst radiologists in the assessment of fistulising perianal CD using the modified 
Van Assche index, but only “slight” to “moderate” inter-rater reliability. Standardized 
scoring definitions and modifications to the van Assche index developed through a 
consensus process enabled us to characterize the greatest sources of 
disagreement, thus generating recommendations that may improve inter-rater 
reliability. The modified van Assche index derived through a mixed effects modelling 
approach has the potential for use in routine clinical practice to more consistently 
assess changes in disease acitivity, as well within clinical trials to evaluate new 
therapies. 
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Table 1. The original and modified Van Assche items 
 
 
Descriptor Original Index1 Item 
Weight 
Modified  Index Item 
Weight 
Definition developed through initial 
consensus2 
Number of 
fistula tracts 
o None 0 o None 0  
 o Single, 
unbranched 
1 o Single, 
unbranched 
1  
 o Single, branched 2 o Single, branched 2 
 
 
 o Multiple 3 o Multiple 3  
Location3   o Submucosal 0 Tract lies superficial to the internal sphincter 
 
   o Intersphincteric 1 Tract extends through the internal sphincter to 
the intersphincteric plane then to the perineal 
skin 
 o Transsphincteric 2 o Transsphincteric 2 Tract extends via the internal and external anal 
sphincter (or puborectalis muscle) into the 
ischioanal fossa then to the perineal skin 
 
 o Extra- or 
intersphincteric 
1 o Extrasphincteric 3 Tract extends through the ischioanal fossa, 
upwards and through the levator ani muscles to 
the rectal wall completely outside the sphincter 
mechanism 
 
 o Suprasphincteric 3 o Suprasphincteric 4 Tract extends via intersphincteric space, then 
tracts superiorly to above the puborectalis 
muscle (ie, above the anorectal junction) before 
curving downward through the levator muscle 
lateral to the external anal sphincter and 
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puborectalis muscle into the ischioanal fossa 
then to the perineal skin 
Extension4   o Absent 0  
 o Infralevatoric 1 o Infralevatoric 1 Extends upward in the ischioanal fossa but 
remains below the levator ani muscle 
 
   o Horseshoe 
configuration 
2 Extends into the intersphincteric space on both 
sides of the midline 
 
 o Supralevatoric 2 o Supralevatoric 3 Extends upward in the intersphincteric plane 
and over the top of the levator ani muscle 
Hyperintensity 
on T2-weighted 
images5 
o Absent 0 o Absent 0 No hyperintensity visible, only scar tissue 
 
 o Mild 4 o Mild 1 Slight increase in signal intensity but less than 
nearby, in- plane vessels 
 
 o Pronounced 8 o Pronounced 2 Tract showing equal or greater signal 
hyperintensity than nearby in-plane vessels 
Collections 
(cavities > 3 mm 
diameter) 
o Absent 0    
 o Present 4    
Rectal wall 
involvement 
o Normal 0 o Normal 0 Normal appearance of rectal wall 
 
 o Thickened 2 o Thickened 1 Thickened rectal wall (eg, >  3 mm when 
distended) 
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   o Increased signal 
intensity 
2 Hyperintensity of the rectal wall on fat saturated 
T2-weighted images (compared to nearby, in-
plane vessels), mural stratification and/or 
perimural infiltrate 
Presence of a 
recto/anovaginal 
tract 
  o Absent 0 No recto/anovaginal tract 
   o Rectovaginal 
tract 
1 Fistula arises from rectal mucosa 
 
   o Anovaginal tract 2 Fistula arises from anal mucosa 
Inflammatory 
mass4  
  o Absent 0 No inflammatory mass 
 
   o Diffuse 1 Diffuse inflammation of surrounding tissues 
 
   o Focal 2 Lesion > 3 mm in diameter on T2-weighted 
images (but does not include linear tracts with 
diameter > 3mm) with diffuse enhancement on 
T1-weighted post contrast images (ie, 
granulation tissue) 
 
   o Collection-small 3 Circumscribed cavity 3-10 mm in diameter (but 
does not include linear tracts with diameter > 3 
mm). 
Hyperintense appearance on fat saturated T2-
weightedimages with rim enhancement on T1-
weighted post-contrast images 
 
   o Collection-
medium 
4 As defined above except diameter measures 
11-20 mm 
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   o Collection-large 5 As defined above except diameter measures 
>20 mm 
Hyperintensity 
of primary tract 
or extensions on 
post-contrast  
T1-weighted 
images5 
  o Absent 0 No hyperintensity visible 
   o Mild 1 Slight increase in signal intensity but less than 
nearby, in- plane vessels 
  
   o Pronounced 2 Tract showing equal or greater signal 
hyperintensity than nearby in-plane vessels 
Dominant 
feature of 
primary tract 
and extensions 
  o Predominantly 
fibrous 
0 > 50% of tract has a fibrotic appearance (ie, 
hypointense on fat saturated T2-weighted 
images)  
 
   o Predominantly 
filled with 
granulation 
tissue 
1 > 50% of tract is filled with granulation tissue 
(ie, hyperintense on fat saturated T2-weighted 
images with enhancement of contents and wall 
on T1-weighted post-contrast images) 
 
   o Predominantly 
filled with fluid or 
pus 
2 > 50% of tract is filled with fluid or pus (ie, 
hyperintense on fat saturated T2-weighted 
images with no enhancement of contents on fat 
saturated T1-weighted post-contrast images 
[though lining of tract may enhance]) 
1The original van Assche index consists of six anatomical and (weighted) inflammatory disease parameters including assessment 
of; the numbers of fistula tracts (0 – 3), the location of fistulas (1 – 3), extension of fistulas (1 or 2), hyperintensity on T2-weighted 
images (0, 4, or 8), presence of collections (defined as cavities >3 mm in diameter) (0 or 4) and rectal wall involvement (score 0 or 
2). The total score ranges from 0 to 22; 2Definitions were applied to modified index only; 3Adapted from the St. Mark’s Classification 
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in the modified index (the most dominant feature is assessed for both the original and modified indices); 4For the modified index, all 
relevant findings are identified; the highest score is chosen; 5For the modified index, extensions were also assessed and the most 
severe lesion was rated by comparing signal intensity with nearby, in-plane vessels in the modified index; images were fat 
saturated 
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Table 2. Reliability* of the VAS, original and modified van Assche indices.  
 
 Reliability (95% CI) 
Intra-rater ICC Inter-rater ICC 
VAS   
Severity of inflammatory perianal disease activity 0.82 (0.75, 0.86) 0.64 (0.53, 0.72) 
Complexity of perianal disease 0.86 (0.81, 0.89) 0.41 (0.28, 0.51) 
Global assessment  
(combined inflammatory activity and complexity) 
0.86 (0.82, 0.89) 0.58 (0.47, 0.66) 
   
Original Van Assche Index   
Number of fistula tracts 0.74 (0.65, 0.82) 0.35 (0.20, 0.51) 
Location 0.59 (0.48, 0.70) 0.30 (0.18, 0.41) 
Extension 0.77 (0.68, 0.85) 0.17 (0.06, 0.28) 
Hyperintensity on T2-weighted images 0.70 (0.59, 0.78) 0.54 (0.42, 0.64) 
Collections (cavities > 3 mm diameter) 0.80 (0.71, 0.88) 0.61 (0.46, 0.73) 
Rectal wall involvement 0.71 (0.63, 0.77) 0.27 (0.17, 0.37) 
Total score 0.86 (0.81, 0.90) 0.66 (0.52, 0.76) 
   
Modified Van Assche Index   
Number of fistula tracts 0.74 (0.65, 0.82) 0.35 (0.20, 0.51) 
Location (according to St Mark’s classification) 0.70 (0.59, 0.79) 0.46 (0.29, 0.59) 
Extension 0.77 (0.68, 0.84) 0.48 (0.33, 0.61) 
Hyperintensity on T2-weighted images 0.70 (0.58, 0.78) 0.54 (0.42, 0.63) 
Rectal wall involvement  0.71 (0.62, 0.78) 0.22 (0.13, 0.31) 
Presence of a recto/anovaginal tract 0.85 (0.71, 0.94) 0.15 (0.02, 0.25) 
Inflammatory mass 0.84 (0.77, 0.89) 0.59 (0.43, 0.71) 
Hyperintensity on post contrast T1-weighted 
images 
0.72 (0.64, 0.79) 0.40 (0.27, 0.50) 
Dominant feature of primary tract & extensions 0.74 (0.65, 0.80) 0.37 (0.23, 0.49) 
Total score (simple sum) 0.90 (0.86, 0.93) 0.67 (0.55, 0.75) 
*Intra- and inter-rater reliability was interpreted using benchmarks described by Landis and 
Koch, whereby intraclass correlation coefficients (ICCs) of <0.0, 0.0–0.20, 0.21–0.4, 0.41–
0.6, 0.61-0.8, and >0.81 constitute ‘poor,’ ‘slight,’ ‘fair,’ ‘moderate,’ ‘substantial’ and ‘almost 
perfect’ reliability, respectively. 
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Table 3. Items and definitions for the modified van Assche index based on the RAND consensus 
Descriptor (score the 
most severe) 
Modified  Index Definition developed through RAND consensus 
Number of fistula tracts o Single, unbranched 
 
 
 o Complex Single branched tract or multiple tracts 
 
Location o Submucosal  Tract lies superficial to the internal sphincter 
 
 o Intersphincteric  Tract extends through the internal sphincter to the intersphincteric plane 
then to the perineal skin 
 
 o Transsphincteric  Tract extends via the internal and external anal sphincter (or puborectalis 
muscle) into the ischioanal fossa then to the perineal skin 
 
 o Extrasphincteric Tract extends through the ischioanal fossa, upwards and through the levator 
ani muscles to the rectal wall completely outside the sphincter mechanism 
 
 o Suprasphincteric  Tract extends via intersphincteric space, then tracts superiorly to above the 
puborectalis muscle (ie, above the anorectal junction) before curving 
downward through the levator muscle lateral to the external anal sphincter 
and puborectalis muscle into the ischioanal fossa then to the perineal skin 
 
Extension o Absent No extension 
 
 o Infralevatoric Extends upward in the ischioanal fossa but remains below the levator ani 
muscle 
 
 o Supralevatoric Any extension in the supralevatoric space (ie, above where the levator plate 
is connected to the anorectum) 
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 o Horseshoe configuration Extends into the intersphincteric space on both sides of the midline 
 
Hyperintensity on            
T2-weighted images1 
o Absent No hyperintensity visible, only scar tissue 
 
 o Mild Slight increase in signal intensity but less than nearby, in- plane vessels 
 
 o Pronounced Tract showing equal or greater signal hyperintensity than nearby in-plane 
vessels 
Proctitis* o Absent Normal appearance of rectal wall 
 
 o Present Increased wall thickness and size of mesorectal lymph nodes (> 5mm), 
creeping fat, increased perimural T2 signal and enhancement 
Presence of a 
recto/anovaginal tract2 
o Absent No recto/anovaginal tract 
 o Rectovaginal tract Fistula arises from rectal mucosa 
 
 o Anovaginal tract Fistula arises from anal mucosa 
Inflammatory mass2  o Absent No inflammatory mass 
 
 o Diffuse Diffuse inflammation of surrounding tissues 
 
 o Focal Lesion > 3 mm in diameter on T2-weighted images (but does not include 
linear tracts with diameter > 3mm) with diffuse enhancement on T1-weighted 
post contrast images (ie, granulation tissue) 
 
 o Collection-small Circumscribed cavity 3-10 mm in diameter (but does not include linear tracts 
with diameter > 3 mm and if present they should be excluded from the 
measurement of the size of the infiltrate3). 
Hyperintense appearance on fat saturated T2-weighted images with 
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enhancement limited to the rim on T1-weighted post-contrast images 
 
 o Collection-medium As defined above except diameter measures 11-20 mm 
 
 
 o Collection-large As defined above except diameter measures >20 mm 
Hyperintensity of primary 
tract or extensions on 
post-contrast  T1-
weighted images 
o Absent No hyperintensity visible 
 o Mild Slight increase in signal intensity but less than nearby, in- plane vessels 
  
 o Pronounced Tract showing equal or greater signal hyperintensity than nearby in-plane 
vessels 
Dominant feature of 
primary tract and 
extensions 
o Predominantly fibrous > 50% of tract has a fibrotic appearance (ie, hypointense on fat saturated 
T2-weighted images)  
 
 o Predominantly filled with 
granulation tissue 
> 50% of tract is filled with granulation tissue (ie, hyperintense on fat 
saturated T2-weighted images with enhancement of contents and wall on 
T1-weighted post-contrast images) 
 
 o Predominantly filled with fluid 
or pus 
> 50% of tract is filled with fluid or pus (ie, hyperintense on fat saturated T2-
weighted images with no enhancement of contents on fat saturated T1-
weighted post-contrast images [though lining of tract may enhance]) 
*This item and definition should replace rectal wall involvement (see Table 1 for original item and definition). 
1Primary tract and/or extensions; 2Mark all that apply and measure fluid collection only (excluding wall) on the shortest axis 
3Infiltrate describes an inflammatory region as a whole that may or may not include one or more fluid collections.
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Table 4.  Coefficients (standard error) of the items of the modified Van Assche index based on mixed-effects models 
 
Full model P value Reduced model P value 
Standardized 
score1 
      
Number of fistula tracts 0.096 (0.092) 0.30 N/A   
Location (according to St Mark’s classification) 0.032 (0.118) 0.78 N/A   
Extension 0.354 (0.061) <0.001 0.367 (0.060) <0.001 1.5 
Hyperintensity on T2-weighted images 0.433 (0.155) 0.005 0.566 (0.137) <0.001 2.3 
Rectal wall involvement 0.227 (0.080) 0.005 0.250 (0.079) 0.002 1.0 
Presence of a recto/anovaginal tract 0.261 (0.135) 0.053 N/A   
Inflammatory mass 0.289 (0.053) <0.001 0.291 (0.053) <0.001 1.2 
Hyperintensity on post contrast T1-weighted images 0.308 (0.157) 0.051 N/A   
Dominant feature of primary tract & extension 0.320 (0.145) 0.027 0.284 (0.143) 0.048 1.2 
      
Bayesian Information Criterion2 1969.7  1954.0   
1The regression coefficient for each item was standardized by dividing by the smallest coefficient and rounding to allow simple 
calculation. 
2The Bayesian Information Criterion assesses the quality of fit of the model. Lower values for the reduced model indicate superior fit.  
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Figure Legends 
Figure 1. Transsphincteric track with extensive scar tissue.  
Panels A and B represent consecutive coronal oblique T2-weighted images showing 
a transsphincteric track (arrow) with extensive scar tissue (*). The scar tissue 
extends high up (open arrow) in the ischioanal space and has a superior extension 
(open arrow) to the pelvic sidewall. The configuration of the superior extending scar 
tissue might be misinterpreted as the levator plate while the anorectal junction might 
be considered to be just below the level of the transsphincteric course of the track. In 
fact the levator plate is superior to the scar tissue (angulated arrows) as is the 
anorectal junction (arrow head). This misinterpretation may have led to identification 
of a supralevatoric extension for this fistula.  
 
Figure 2. Transphinteric track with limited supralevatoric extension  
Coronal oblique (panel A) and sagittal (panel B) T2-weighted images showing a 
transsphincteric track (arrow) extending just above (open arrow) the levator plate (L), 
the latter resulting in classifying it as (albeit limited) supralevatoric extension of the 
track. The limited extension above the levator plate and anorectal junction (arrow 
head) with the track directly adjacent to the levator plate might have led to different 
interpretations by readers.  
 
Figure 3. The ano-rectal junction. 
To provide superior differentiation between supra- and infralevatoric extensions, this 
junction is now defined as the connection of the levator plane to the ano-rectum and 
is delineated by two arrows in this coronal oblique T2-weighted image.  
33 
 
Authorship statement  
(i) Guarantor of the work: VJ 
(ii) Specific author contributions: MAS, CAJP, BGL, GYZ, MKV, BGF, VJ, JS 
played a role in planning and/or conducting the study; GYZ, LS played a role in the 
statistical analysis of the study data; MAS, CAJP, GYZ, LS, SAT, LMS, CS, JR, 
CYN, VJ, JS played a role in collecting and/or interpreting data, MAS, LMS, VJ 
played a role in drafting the manuscript. MAS, CAJP, BGL, GYZ, LS, SAT, LMS, 
MKV, RK, CS, JR, PH, CYN, WJS, GDH, BGF, VJ, JS played a role in reviewing and 
revising the manuscript for important intellectual content.  
(iii) All authors approved the final version of the manuscript. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
STATEMENT OF INTERESTS  
1. Authors’ declaration of personal interests 
MAS has nothing to disclose.  
CAJP has nothing to disclose. 
BGL has received consulting fees from AbbVie, Takeda, Nestle Health Sciences, 
and Prometheus Labs. 
GYZ has nothing to disclose. 
LS has nothing to disclose. 
SAT is an NIHR senior investigator. 
LMS has nothing to disclose. 
MKV has nothing to disclose. 
RK has received consulting fees from AbbVie, Takeda, and Janssen. 
CS has nothing to disclose. 
JR has nothing to disclose. 
PH has received consulting fees from Abbvie and Takeda; speakers fees from 
Ferring, Falk Pharma, Vifor Pharma, Tillotts Pharma, Chiesi, Takeda and Abbvie. 
CYN has nothing to disclose. 
WJS has served as a consultant to: AbbVie Inc., ActoGeniX NV, AGI Therapeutics, 
Inc., Alba Therapeutics Corporation, Albireo, Alfa Wasserman, Amgen, AM-Pharma 
BV, Anaphore, Astellas Pharma, Athersys, Inc., Atlantic Healthcare Limited, Axcan 
Pharma (now Aptalis), BioBalance Corporation, Boehringer-Ingelheim Inc, Bristol 
Meyers Squibb, Celgene, Celek Pharmaceuticals, Cellerix SL, Cerimon 
Pharmaceuticals, ChemoCentryx, CoMentis, Cosmo Technologies, Coronado 
Biosciences, Cytokine Pharmasciences, Eagle Pharmaceuticals, Eisai Medical 
Research Inc., Elan Pharmaceuticals, EnGene, Inc., Eli Lilly, Enteromedics, Exagen 
35 
 
Diagnostics, Inc., Ferring Pharmaceuticals, Flexion Therapeutics, Inc., Funxional 
Therapeutics Limited, Genzyme Corporation, Genentech (now Roche), Gilead 
Sciences, Given Imaging, Glaxo Smith Kline, Human Genome Sciences, Ironwood 
Pharmaceuticals (previously Microbia Inc.), Janssen (previously Centocor), KaloBios 
Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Lycera Corporation, Meda 
Pharmaceuticals (previously Alaven Pharmaceuticals), Merck Research 
Laboratories, MerckSerono, Millennium Pharmaceuticals (subsequently merged with 
Takeda), Nisshin Kyorin Pharmaceuticals Co., Ltd., Novo Nordisk A/S, NPS 
Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, Inc., PDL 
Biopharma, Pfizer, Procter and Gamble, Prometheus Laboratories, ProtAb Limited, 
Purgenesis Technologies, Inc., Receptos, Relypsa, Inc., Salient Pharmaceuticals, 
Salix Pharmaceuticals, Inc., Santarus, Schering Plough Corporation (acquired by 
Merck), Shire Pharmaceuticals, Sigmoid Pharma Limited, Sirtris Pharmaceuticals, 
Inc. (a GSK company), S.L.A. Pharma (UK) Limited, Targacept, Teva 
Pharmaceuticals, Therakos, Tillotts Pharma AG (acquired by Zeria Pharmaceutical 
Co., Ltd), TxCell SA, UCB Pharma, Viamet Pharmaceuticals, Vascular Biogenics 
Limited (VBL), Warner Chilcott UK Limited; has received speaker’s fees from: 
AbbVie Inc., Bristol Meyers Squibb, and Janssen (previously Centocor); and financial 
support for research from: AbbVie Inc., Bristol Meyers Squibb, Genentech, Glaxo 
Smith Kline, Janssen (previously Centocor), Millennium Pharmaceuticals (now 
Takeda), Novartis, Pfizer, Procter and Gamble Pharmaceuticals, Shire 
Pharmaceuticals, and UCB Pharma. 
GD’H has received consulting and/or lecture fees from AbbVie, ActoGeniX, AIM, 
Boehringer Ingelheim GmbH, Centocor, Chemo Centryx, Cosmo Technologies, Elan 
Pharmaceuticals, enGene, Dr Falk Pharma, Ferring, Galapagos, Giuliani SpA, Given 
36 
 
Imaging, GlaxoSmithKline, Janssen Biologics, MSD, Neovacs, Novo Nordisk, 
Otsuka, PDL BioPharma, Pfizer, Receptos, Salix, SetPoint, Shire Pharmaceuticals, 
Schering-Plough, Takeda, Tillotts Pharma, UCB Pharma, Versant, and Vifor Pharma; 
research grants from AbbVie, Janssen, Given Imaging, MSD, Dr Falk Pharma, and 
PhotoPill; and speaking honoraria from AbbVie, Tillotts, Tramedico, Ferring, MSD, 
UCB Pharma, Norgine, and Shire. 
BGF BGF has received grant/research support from Millennium Pharmaceuticals, 
Merck, Tillotts Pharma AG, AbbVie, Novartis Pharmaceuticals, Centocor Inc., 
Elan/Biogen, UCB Pharma, Bristol-Myers Squibb, Genentech, ActoGenix, and Wyeth 
Pharmaceuticals Inc.; consulting fees from Millennium Pharmaceuticals, Merck, 
Centocor Inc., Elan/Biogen, Janssen-Ortho, Teva Pharmaceuticals, Bristol-Myers 
Squibb, Celgene, UCB Pharma, AbbVie, Astra Zeneca, Serono, Genentech, Tillotts 
Pharma AG, Unity Pharmaceuticals, Albireo Pharma, Given Imaging Inc., Salix 
Pharmaceuticals, Novonordisk, GSK, Actogenix, Prometheus Therapeutics and 
Diagnostics, Athersys, Axcan, Gilead, Pfizer, Shire, Wyeth, Zealand Pharma, 
Zyngenia, GiCare Pharma Inc., and Sigmoid Pharma; and speakers bureaux fees 
from UCB, AbbVie, and J&J/Janssen. 
VJ has received scientific advisory board fees from AbbVie and Sandoz; speakers 
fees from Takeda and Janssen. 
JS has received research-consulting fees from Robarts Clinical Trials.  
 
 
Robarts Clinical Trials began in 1986 as an academic research unit within the 
Robarts Research Institute which is affiliated with University Hospital and the 
University of Western Ontario. A subsequent international (United States of America 
and Netherlands) expansion in 2012 necessitated establishment of a corporate entity 
37 
 
to meet international federal/taxation regulations. All profits from Robarts Clinical 
Trials, Inc. are directed towards academic research. The University of Western 
Ontario is the sole shareholder of Robarts Clinical Trials Inc. None of the authors 
with affiliation to Robarts Clinical Trials, Inc. have an equity position or any shares in 
the corporation. 
 
 
2. Declaration of funding interests: None.  
 
 
